Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02557633 · ClinicalTrials.gov registry record · Phase 1
A Study of Tolerability and Safety of Two New Doses of Grass MATA MPL
A Phase 1 study, sponsored by Allergy Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
NCT02557633 is a Phase 1 study that has completed, run by Allergy Therapeutics. The registered enrollment target is 29 participants.
The verdict
NCT02557633, a Phase 1 study, has completed, sponsored by Allergy Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
Study Summary
There is increasing evidence that the effectiveness of allergy immunotherapy to control symptoms of rhinoconjunctivitis is related to the cumulative dose of allergen or allergoid administered during a single regimen of subcutaneous (SC) injections or of sublingual administration. Two new cumulative doses of the Grass MATA MPL 10200 and 18200 SU (Standardized Units) are being developed to compare with the current dose of 5100 SU. The purpose of this study is to evaluate the tolerability and safety of these two new cumulative dose regimens of Grass MATA MPL compared with placebo in patients with seasonal allergic rhinoconjunctivitis (SAR) due to grass pollen, to enable selection of the best dose to go into a larger scale study to assess the efficacy and safety of the higher cumulative doses.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL Grass MATA MPL 10200
- BIOLOGICAL Grass MATA MPL 18200
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2015-08 |
| Est. Completion | 2016-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02557633
The ClinicalTrials.gov registry entry for NCT02557633 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergy Therapeutics, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02557633 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02557633 about?
NCT02557633 is a clinical study titled "A Study of Tolerability and Safety of Two New Doses of Grass MATA MPL". There is increasing evidence that the effectiveness of allergy immunotherapy to control symptoms of rhinoconjunctivitis is related to the cumulative dose of allergen or allergoid administered during a single regimen of subcutaneous (SC) injections or of sublingual administration. Two new cumulative...
What is the current status of trial NCT02557633?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2015-08. Estimated completion is 2016-10.
What interventions are being tested in trial NCT02557633?
The interventions under investigation include: Placebo (BIOLOGICAL), Grass MATA MPL 10200 (BIOLOGICAL), Grass MATA MPL 18200 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02557633?
This trial is sponsored by Allergy Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.